Carolina Wealth Advisors’s Sonnet BioTherapeutics SONN Stock Holding History

Carolina Wealth Advisors’s Portfolio SONN Stock Details SONN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-32	Closed	-$147	–	286
2025 Q3	$147	Hold	32	–	–	﹤0.01%	226
2025 Q2	$40	Hold	32	–	–	﹤0.01%	268
2025 Q1	$43	Hold	32	–	–	﹤0.01%	282
2024 Q4	$47	Buy	+32	New	+$112	﹤0.01%	296

Other funds holding SONN

FAM

Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return

Carolina Wealth Advisors's SONN Position: Q4 2025 in Review

Carolina Wealth Advisors sold out of Sonnet BioTherapeutics (SONN) in Q4 2025, closing a stake of 32 shares — an estimated $147 sold.

Carolina Wealth Advisors first reported a position in SONN in Q4 2024 and held it in 4 quarters. The position peaked at $147 in Q3 2025. 1 fund tracked by Wall St. Rank holds SONN as of Q4 2025.

Carolina Wealth Advisors reported no remaining Sonnet BioTherapeutics position as of Q4 2025 after selling out during the quarter.
Carolina Wealth Advisors sold 32 Sonnet BioTherapeutics shares in Q4 2025, an estimated $147.
Carolina Wealth Advisors first reported a position in Sonnet BioTherapeutics in Q4 2024 and held it in 4 quarters.
Carolina Wealth Advisors's Sonnet BioTherapeutics position peaked at $147 in Q3 2025.
1 fund tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q4 2025.

Based on Carolina Wealth Advisors's 13F filing for Q4 2025, filed 21 Jan 2026.